Molecular Templates, Inc.

94 articles about Molecular Templates, Inc.

• Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

  11/13/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2023.

• Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

  11/2/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.

• Molecular Templates to Participate in Upcoming November 2023 Investor Conferences

  11/1/2023

  Molecular Templates, Inc. announced participation in the following upcoming investor conferences.

• Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

  9/28/2023

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer.

• Molecular Templates Announces 1-for-15 Reverse Stock Split

  8/11/2023

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company’s common stock at a special meeting of the Company held on August 11, 2023.

• Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

  8/10/2023

  Molecular Templates, Inc.  today reported financial results and business updates for the second quarter of 2023.

• Molecular Templates Announces Executive Leadership Changes - August 02, 2023

  8/2/2023

  Molecular Templates, Inc. announced executive management changes to implement its next phase of development.

• Molecular Templates Announces Up to $40 Million Private Placement Offering

  7/13/2023

  Molecular Templates, Inc. announced today it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $40 million in gross proceeds to MTEM through a private placement in two tranches.

• Molecular Templates Announces Debt Payoff and Restructuring

  6/17/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.

• Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

  6/1/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial.

• Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/26/2023

  Molecular Templates, Inc. announced the presentation of a poster at the American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.

• Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

  5/15/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the first quarter of 2023.

• Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

  4/7/2023

  Molecular Templates, Inc., announced that the U.S. Food and Drug Administration informed MTEM that it has placed a partial clinical hold on the Phase 1 study of MT-0169 based on previously disclosed cardiac adverse events noted in two patients dosed at 50 mcg/kg that prompted the dose reduction to 5 mcg/kg last year.

• Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

  3/30/2023

  Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

• Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

  3/9/2023

  Molecular Templates, Inc. has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.

• Molecular Templates Announces Participation in Upcoming March 2023 Conferences

  3/1/2023

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences.

• Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

  12/2/2022

  Molecular Templates, Inc. announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

• Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

  11/23/2022

  Molecular Templates, Inc. announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler’s 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022.

• Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

  11/10/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2022.

• Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

  11/4/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA.